Orexin/hypocretin in psychiatric disorders: present state of knowledge and future potential.
Borgland
Stephanie L
SL
Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada. borgland@interchange.ubc.ca
Labouèbe
Gwenaël
G
D001921:Brain / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D001523:Mental Disorders / Q000188:drug therapy / Q000378:metabolism*; D009479:Neuropeptides / Q000378:metabolism*; D000068797:Orexins; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000378:metabolism
D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins